Richard I. Steinhart
CIK: 0001293789
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (41 total)
- Sep 2, 2026ATNM
Actinium Pharmaceuticals, Inc.
Award(A)Direct62.8K shares- - Jun 15, 2026BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct35 shares- - May 20, 2026BTAI
BioXcel Therapeutics, Inc.
Sale(S)Direct6.8K shares at avg. $1.08$7K - May 12, 2026ATOS
ATOSSA THERAPEUTICS, INC.
Award(A)Direct10K shares- - May 4, 2026BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct17.5K shares- - May 1, 2026BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct9K shares- - Mar 15, 2026BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct35 shares- - Mar 14, 2026BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct33 shares- - Jan 1, 2026BTAI
BioXcel Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
70K shares- - Dec 15, 2025BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct35 shares- - Dec 14, 2025BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct33 shares- - Sep 15, 2025BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct35 shares- - Sep 14, 2025BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct33 shares- - Aug 1, 2025BTAI
BioXcel Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
9K shares- - Jul 22, 2025BTAI
BioXcel Therapeutics, Inc.
Award(A)Direct4.4K shares- - Jul 22, 2025BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct625 shares- - Jun 15, 2025BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct35 shares- - Jun 14, 2025BTAI
BioXcel Therapeutics, Inc.
Exercise(M)Direct33 shares- - May 15, 2025ATOS
ATOSSA THERAPEUTICS, INC.
Award(A)DirectStock Option (right to buy)
125K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
2.5K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
2.5K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
2.5K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
8.3K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
8.3K shares- - Mar 31, 2025ATNM
Actinium Pharmaceuticals, Inc.
Disposition(D)DirectStock Option (Right to Buy)
18.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 2, 2026 |  ATNM Actinium Pharmaceuticals, Inc. | Award(A) | 62,800 | - | $0 | Direct |
| Jun 15, 2026 |  BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 35 | - | $0 | Direct |
| May 20, 2026 | BTAI BioXcel Therapeutics, Inc. | Sale(S) | 6,845 | $1.08 | $7,427 | Direct |
| May 12, 2026 |  ATOS ATOSSA THERAPEUTICS, INC. | Award(A) | 10,000 | - | $0 | Direct |
| May 4, 2026 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 17,500 | - | $0 | Direct |
| May 1, 2026 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 9,000 | - | $0 | Direct |
| Mar 15, 2026 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 35 | - | $0 | Direct |
| Mar 14, 2026 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 33 | - | $0 | Direct |
| Jan 1, 2026 | BTAI BioXcel Therapeutics, Inc. | Award(A) Restricted Stock Units | 70,000 | - | - | Direct |
| Dec 15, 2025 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 35 | - | - | Direct |
| Dec 14, 2025 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 33 | - | - | Direct |
| Sep 15, 2025 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 35 | - | - | Direct |
| Sep 14, 2025 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 33 | - | - | Direct |
| Aug 1, 2025 | BTAI BioXcel Therapeutics, Inc. | Award(A) Restricted Stock Units | 9,000 | - | - | Direct |
| Jul 22, 2025 | BTAI BioXcel Therapeutics, Inc. | Award(A) | 4,375 | - | - | Direct |
| Jul 22, 2025 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 625 | - | - | Direct |
| Jun 15, 2025 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 35 | - | - | Direct |
| Jun 14, 2025 | BTAI BioXcel Therapeutics, Inc. | Exercise(M) | 33 | - | - | Direct |
| May 15, 2025 | ATOS ATOSSA THERAPEUTICS, INC. | Award(A) Stock Option (right to buy) | 125,000 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 2,500 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 2,500 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 2,500 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 8,333 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 8,333 | - | - | Direct |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | Disposition(D) Stock Option (Right to Buy) | 18,351 | - | - | Direct |
1-25 of 41 transactions
About Steinhart Richard I
Steinhart Richard I (SEC CIK 0001293789) files insider reports with the SEC as Director of Actinium Pharmaceuticals, Inc. (ATNM), Chief Financial Officer of BioXcel Therapeutics, Inc. (BTAI) and Director of ATOSSA THERAPEUTICS, INC. (ATOS).
Signal8 holds 20 ownership filings by Steinhart Richard I, all Form 4s, filed between Sep 17, 2024 and Sep 4, 2026. Those filings report 41 transactions, from Jul 22, 2024 to Sep 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Steinhart Richard I's filings is in NEW YORK, NY.
Recent filings by Steinhart Richard I
- Sep 2, 2026: Grant or award of ATNM shares (Form 4, code A).
- Jun 15, 2026: Option exercise of BTAI shares (Form 4, code M).
- May 20, 2026: Open-market sale of BTAI shares (Form 4, code S).
- May 12, 2026: Grant or award of ATOS shares (Form 4, code A).
- May 4, 2026: Option exercise of BTAI shares (Form 4, code M).
Other insiders filing for Actinium Pharmaceuticals, Inc. (ATNM)
- David Matthew T, Chief Financial Officer
- Kamal Adeela, Chief Scientific Officer
- Heeger Steffen Wilhem, Chief Medical Officer
- Shetty Ajit, Director
- Nicholson, C. David, Director
- Almenoff June Sherie, Director